Rapport Therapeutics, Inc./$RAPP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Rapport Therapeutics, Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
- Ticker
- $RAPP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 84
- Headquarters
- Boston, United States
- Website
- www.rapportrx.com
RAPP Metrics
BasicAdvanced
$1.5B
-
-$3.18
1.40
-
Price and volume
Market cap
$1.5B
Beta
1.4
52-week high
$52.93
52-week low
$22.06
Average daily volume
1.2M
Financial strength
Current ratio
20.066
Quick ratio
19.466
Long term debt to equity
0.018
Total debt to equity
0.024
Profitability
EBITDA (TTM)
-166.714
Gross margin (TTM)
-149.40%
Net profit margin (TTM)
-752.35%
Operating margin (TTM)
-838.08%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-21.97%
Return on equity (TTM)
-33.33%
Valuation
Price to revenue (TTM)
61.77
Price to book
3.2
Price to tangible book (TTM)
3.2
Price to free cash flow (TTM)
-10.194
Free cash flow yield (TTM)
-9.81%
Free cash flow per share (TTM)
-2.557
Growth
Earnings per share change (TTM)
16.88%
What the Analysts think about RAPP
Analyst ratings (Buy, Hold, Sell) for Rapport Therapeutics, Inc. stock.
Analyst projections of the future price of Rapport Therapeutics, Inc. stock.
Bulls say / Bears say
RAP-219 showed durable activity in a 30-patient focal-seizure study: median clinical seizures fell 59% versus baseline in weeks 13–16, and its estimated half-life is 22 days. Two Phase 3 trials are now enrolling, moving the lead programme into pivotal testing. (SEC)
RAP-219 also met the primary and a secondary endpoint in a Phase 2 bipolar-mania trial, with no serious adverse events during the three-week treatment period. This gives the same drug a second clinical opportunity beyond epilepsy. (SEC)
The newly priced financing is expected to extend the company’s cash runway through the end of 2029. That gives Rapport capital to pursue its late-stage trials and other pipeline work without an immediate need to raise again, assuming spending stays within its estimates. (GlobeNewswire)
The focal-seizure efficacy signal comes from a small Phase 2a cohort of 30 patients and follow-up data, while the pivotal Phase 3 trials have yet to report results. The earlier signal may not hold up in larger controlled studies. (SEC)
In bipolar mania, the placebo-adjusted improvement was 3.1 points with a p-value of 0.045, only just below the conventional statistical threshold. More patients stopped treatment in the RAP-219 arm than on placebo, 24.6% versus 11.8%, raising questions about the size and durability of the benefit. (SEC)
Rapport’s financing includes a large new share offering and $150 million of convertible notes. The equity issuance dilutes existing holders, while conversion of the notes could add further shares later. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
RAPP Financial Performance
Revenues and expenses
RAPP Earnings Performance
Company profitability
Upcoming events
No upcoming events
RAPP News
AllArticlesVideos
Funds containing RAPP
Fund name | Fund size | $RAPP weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.08% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.